ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lilly licenses AC Immune’s tau aggregation inhibitors

by Lisa Jarvis
December 16, 2018 | APPEARED IN VOLUME 96, ISSUE 49

 

Placing yet another bet in the risky area of Alzheimer’s disease drug development, Eli Lilly and Co. will pay AC Immune $81 million as part of a pact to develop small-molecule tau aggregation inhibitors. Previously focused on amyloid-β, Alzheimer’s drug development has largely shifted to tau, the other hallmark protein in the brains of people with the disease. AC Immune’s small molecules lower the levels of tau that is misfolded or in clumps. Lilly has seen multiple Alzheimer’s drugs fail in large, late-stage clinical trials.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment